OncoMatch/Clinical Trials/NCT05422690
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Is NCT05422690 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Induction Chemotherapy Triplet Therapy and Consolidation Doublet Therapy: for intrahepatic cholangiocarcinoma.
Treatment: Induction Chemotherapy Triplet Therapy · Consolidation Doublet Therapy: — The purpose of this research is to see if combining gemcitabine, cisplatin and Durvalumab chemotherapy treatments with a direct tumor therapy called Yittrium-90, will work better together to shrink the tumor and control cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: adjuvant therapy with capecitabine
Previous treatment with chemotherapy, intra-arterial or radiotherapy for iCCA is exclusionary, with the exception of adjuvant therapy with capecitabine which is allowed.
Cannot have received: intra-arterial therapy
Previous treatment with chemotherapy, intra-arterial or radiotherapy for iCCA is exclusionary, with the exception of adjuvant therapy with capecitabine which is allowed.
Cannot have received: radiotherapy
Previous treatment with chemotherapy, intra-arterial or radiotherapy for iCCA is exclusionary, with the exception of adjuvant therapy with capecitabine which is allowed.
Lab requirements
Liver function
Noncirrhotic liver required; Child-Pugh score must be less than 5; Child-Pugh B7 or greater cirrhosis excluded; Serum albumin < 3 g/dL excluded; Serum bilirubin > 2 mg/dL excluded; AST or ALT > 5x ULN excluded
Noncirrhotic liver ... Child-Pugh score must be less than 5 ... Serum albumin < 3 g/dL ... Serum bilirubin > 2 mg/dL ... AST or ALT > 5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Keary Janet · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify